Westerterp Marinke, Sloof Gerrit W, Hoekstra Otto S, Ten Kate Fiebo J W, Meijer Gerrit A, Reitsma Johannes B, Boellaard Ronald, van Lanschot J Jan B, Molthoff Carla F M
Department of Surgery, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
J Cancer Res Clin Oncol. 2008 Feb;134(2):227-36. doi: 10.1007/s00432-007-0275-0. Epub 2007 Jul 25.
Variable uptake of 18FDG has been noticed in positron emission tomography (PET) studies of patients with oesophageal adenocarcinoma. The aim of the present study was to investigate biological parameters involved in 18FDG uptake in oesophageal adenocarcinoma for selection of patients with increased 18FDG uptake and prediction of prognostic value of 18FDG PET.
Preoperative PET scans were performed in 26 patients with histologically proven oesophageal adenocarcinoma. 18FDG uptake was semiquantitatively measured by SUV(BSAg. )Tumour sections were stained by immunohistochemistry for angiogenic markers (VEGF, CD31), glucose transporter-1 (Glut-1), hexokinase (HK) isoforms, for proliferation marker (Ki67), for macrophage marker (CD68) and for apoptosis marker (cleaved caspase-3). Cell densities, differentiation grade, degree of necrosis and mucus, T-stage and tumour size were assessed. In addition follow-up was analysed.
No association was found between 18FDG uptake and angiogenic markers. In contrast, a significant correlation was found between 18FDG uptake and Glut-1 expression. No correlations were found between 18FDG uptake and HK isoforms, Ki67 or cleaved caspase-3. Also, no correlations were found between 18FDG uptake and cell density, differentiation grade, CD68, mucus and necrosis. However, there was a significant correlation between 18FDG uptake and tumour size and between 18FDG uptake and tumour recurrence.
Glut-1 expression and tumour size seem parameters associated with 18FDG uptake in patients with biopsy proven oesophageal adenocarcinoma, and may be used to select oesophageal cancer patients in whom 18FDG-PET is of diagnostic value and may predict disease outcome.
在食管腺癌患者的正电子发射断层扫描(PET)研究中,已注意到18氟脱氧葡萄糖(18FDG)摄取存在差异。本研究的目的是调查食管腺癌中与18FDG摄取相关的生物学参数,以筛选18FDG摄取增加的患者,并预测18FDG PET的预后价值。
对26例经组织学证实为食管腺癌的患者进行术前PET扫描。通过标准化摄取值(SUV)对18FDG摄取进行半定量测量。肿瘤切片采用免疫组织化学方法检测血管生成标志物(血管内皮生长因子(VEGF)、CD31)、葡萄糖转运蛋白-1(Glut-1)、己糖激酶(HK)同工型、增殖标志物(Ki67)、巨噬细胞标志物(CD68)和凋亡标志物(裂解的半胱天冬酶-3)。评估细胞密度、分化程度、坏死和黏液程度、T分期及肿瘤大小。此外,还对随访情况进行了分析。
未发现18FDG摄取与血管生成标志物之间存在关联。相反,发现18FDG摄取与Glut-1表达之间存在显著相关性。未发现18FDG摄取与HK同工型、Ki67或裂解的半胱天冬酶-3之间存在相关性。此外,也未发现18FDG摄取与细胞密度、分化程度、CD68、黏液和坏死之间存在相关性。然而,18FDG摄取与肿瘤大小之间以及18FDG摄取与肿瘤复发之间存在显著相关性。
在经活检证实的食管腺癌患者中,Glut-1表达和肿瘤大小似乎是与18FDG摄取相关的参数,可用于筛选18FDG-PET具有诊断价值且可能预测疾病转归的食管癌患者。